How does insulin resistance affect hair?

Raised insulin lowers sex hormone binding globulin, which increases the free androgen available to act at the follicle. The route to the hair runs through the androgen pathway.

Can my labs look normal and this still apply?

Fasting glucose can read as fine while insulin is quietly compensating. The article covers what else is worth asking for.

Is this the same thing as PCOS?

They overlap substantially but are not identical. Insulin resistance is common in PCOS and also occurs without it.

Insulin Resistance, Metabolic Syndrome and Thinning Hair

17 août 2026

By Dr. Susan Lin, MD | MD HAIR | La Cañada Ventures, Inc.
Published on mdhair.com — Hormonal & Life Stage Hair Loss Series

Your labs came back fine. Glucose normal. Cholesterol borderline but nobody seemed worried. You were told your thyroid was fine and your iron was fine and that hair thinning at your age is just something that happens.

Meanwhile you are tired after meals in a way you did not used to be, your waistband has moved without much explanation, the afternoon energy crash has become a fixture, and your part line is widening. And nobody has connected any of it, because those symptoms belong to four different specialties and hair belongs to none of them.

I want to draw a line between them, because there is a real physiological connection between how your body handles insulin and how much androgen reaches your hair follicles — and it is one of the few contributors to thinning hair that responds meaningfully to things you can actually do. It is also one of the most commonly missed, for a specific and frustrating reason: the blood test that would show it earliest is usually not ordered.

What Insulin Resistance Actually Is

Insulin's principal job is to move glucose out of the bloodstream and into cells. Insulin resistance means the tissues that should respond to that signal — muscle, liver, fat — respond less well to a given amount of it.

The body's response is to make more. So for years, sometimes decades, blood glucose stays normal because insulin is running high enough to force it to be normal. This is the compensated phase, and it is where a great many people live for a very long time. Fasting glucose: normal. HbA1c: normal or creeping. Everything appears fine on the standard panel, because the standard panel measures the outcome and not the effort required to achieve it.

Insulin resistance is therefore invisible on the tests most people are given, right up until it is not. Only when the pancreas can no longer keep up does glucose rise and the diagnosis becomes obvious.

Metabolic syndrome is the clustered form: abdominal adiposity, raised triglycerides, low HDL cholesterol, raised blood pressure and raised fasting glucose. Meeting three of the five criteria defines it, and it is common — a substantial fraction of adults meet the definition (Alberti et al., 2009).

The Link to Hair: Hyperinsulinaemia Lowers SHBG

Here is the connection, and it runs through a single protein.

Sex hormone-binding globulin (SHBG) is made by the liver and circulates in the blood, binding testosterone with high affinity. Bound testosterone is not biologically available — it cannot enter tissues and act on receptors. Only the free fraction, a small percentage of the total, does anything. SHBG is therefore the volume control on androgen exposure.

Insulin suppresses SHBG production by the liver. This is not an inference from correlations; it was shown directly in hepatoma cell culture, where insulin inhibited SHBG production (Plymate et al., 1988), and demonstrated in vivo when reducing insulin levels in women with polycystic ovary syndrome raised serum SHBG (Nestler et al., 1991). The inverse relationship between insulin resistance and SHBG is one of the more consistent findings in metabolic endocrinology (Wallace et al., 2013).

The consequence follows arithmetically. If SHBG falls and total testosterone stays exactly the same, the free, active fraction rises. You can have a perfectly unremarkable total testosterone on a lab report and a meaningfully elevated free testosterone, purely because there is less protein available to bind it.

What Free Androgen Does at the Follicle

Free testosterone diffuses into tissues, including scalp skin. At the follicle, the enzyme 5-alpha-reductase converts it into dihydrotestosterone (DHT), which binds the androgen receptor in the dermal papilla with considerably greater affinity than testosterone itself.

In follicles that are genetically sensitive — and this sensitivity is regional, which is why the part, crown and frontal scalp are affected while the occiput usually is not — androgen receptor signalling progressively shortens the anagen growth phase. Each cycle the follicle grows for less time and produces a shorter, finer hair. Over years, terminal hairs are replaced by hairs too fine to contribute to coverage. Sawaya and Price documented the elevated 5-alpha-reductase activity and androgen receptor levels in affected scalp follicles that underpin this regional susceptibility (Sawaya & Price, 1997).

So the chain is: insulin resistance → compensatory hyperinsulinaemia → suppressed hepatic SHBG → raised free testosterone → more substrate for follicular 5-alpha-reductase → more DHT at susceptible follicles → accelerated miniaturization.

Nothing in that chain requires a hormonal disease. It requires only that insulin be chronically elevated, which is exactly the state that standard glucose testing is designed not to detect.

What the Observational Literature Shows — Read Honestly

There is a body of research linking pattern hair loss to metabolic and cardiovascular markers. It is worth knowing, and it is worth reading with discipline.

Early androgenetic alopecia has been proposed as a clinical marker of insulin resistance (Matilainen et al., 2000). Studies in young men with androgenetic alopecia have reported higher rates of insulin resistance than in controls (González-González et al., 2009), and case–control work has found associations between early-onset pattern hair loss and a cluster of cardiovascular risk factors in both sexes (Arias-Santiago et al., 2010).

Three honest caveats.

First, these are largely cross-sectional and case–control studies. They establish association, not that insulin resistance caused the hair loss in any individual. Both conditions share androgen biology and both increase with age and adiposity, so confounding is real.

Second, effect sizes vary considerably between studies, and some have not replicated. This is a genuine signal, not a settled quantity.

Third — and this is the useful part — the mechanism is independently established even where the epidemiology is mixed. The insulin–SHBG relationship is demonstrated at the level of the hepatocyte, not merely observed in populations. So the reasoning does not depend on the association studies being definitive: we know how insulin lowers SHBG and we know what free androgen does at a susceptible follicle.

The practical upshot is modest and sensible. This is one contributing driver among several, worth identifying because it is modifiable — not a unified theory of hair loss.

The PCOS Overlap

Polycystic ovary syndrome is where this mechanism is most concentrated, and it is the reason many women reading this will recognise the whole picture at once. Insulin resistance is a core feature of PCOS for a large proportion of those affected, and the SHBG suppression it produces is a major contributor to the clinical androgen excess — including the scalp thinning that often coexists, confusingly, with unwanted hair growth elsewhere.

I have written about that syndrome in full elsewhere on this site rather than compress it here, and if irregular cycles, acne, or hirsutism are part of your picture, that is the article to read next: PCOS and Hair Loss: When Your Own Hormones Turn Against Your Follicles.

What belongs here is the point that generalises beyond PCOS: you do not need a PCOS diagnosis for insulin to be lowering your SHBG. The same mechanism operates on a spectrum, in women without the syndrome and in men, wherever chronic hyperinsulinaemia is present.

What to Ask For

If this article describes you, the appointment you want is with your primary care physician, and the request is for metabolic assessment rather than a hair workup. The tests that matter:

Fasting insulin. This is the one usually missing, and it is the one that detects the compensated phase. A normal glucose achieved with a high insulin is a completely different physiological state from a normal glucose achieved with a low one, and only measuring insulin distinguishes them. Fasting insulin together with fasting glucose also allows calculation of HOMA-IR, a standard index of insulin resistance.
Fasting glucose and HbA1c — the conventional pair, giving current and roughly three-month average glycaemia.
A full lipid panel, with attention to triglycerides and HDL; the triglyceride-to-HDL ratio is a widely used surrogate marker of insulin resistance.
Waist circumference and blood pressure — unglamorous, free, and two of the five metabolic syndrome criteria (Alberti et al., 2009).
SHBG, total and free testosterone, and DHEA-S, if there are androgenic signs.
Liver enzymes, since hepatic steatosis frequently accompanies insulin resistance.
And, because they matter independently for hair: full thyroid panel, serum ferritin, and vitamin D.

A note that belongs here: high-dose biotin supplements can interfere with laboratory immunoassays — interference is generally described from around 5 mg upward, a dose common in hair supplements. Tell your physician what you take before blood is drawn.

What Actually Moves the Needle

The reason to identify this is that it responds to intervention better than almost anything else on the hair-loss list.

Resistance training is the most underrated intervention here. Skeletal muscle is the principal site of insulin-mediated glucose disposal, and it takes up glucose during and after contraction through pathways that are partly independent of insulin. More muscle mass, contracted regularly, means more capacity to clear glucose at a lower insulin cost. Two to three sessions a week of progressive resistance work does more for insulin sensitivity per hour than most people expect, and it is complementary to rather than replaced by cardiovascular exercise.

Reduce the glycaemic load, not merely the calories. The target is the size and speed of the insulin excursion after eating, not weight loss per se. In practice: protein and fibre at every meal, whole rather than refined carbohydrate sources, and particular attention to liquid sugars, which arrive fastest and provoke the largest insulin response. Walking for ten to fifteen minutes after a meal blunts the postprandial glucose rise measurably and costs nothing.

Sleep is a metabolic intervention, not a lifestyle preference. Experimental sleep restriction reduces insulin sensitivity in healthy adults within days (Spiegel et al., 1999; Buxton et al., 2010). If you are sleeping five hours, no dietary change will fully compensate, and this is also the point at which the metabolic and the cortisol stories converge — both of which reach the follicle.

Modest, sustained weight reduction where relevant. Loss of visceral adipose tissue improves insulin sensitivity disproportionately to the amount lost. But two cautions belong here from a hair perspective: rapid or severely restrictive weight loss is itself a well-documented trigger for telogen effluvium, and protein adequacy must be maintained. Losing weight in a way that shocks the follicle defeats the purpose.

Timeline, honestly. Insulin sensitivity begins improving within weeks of consistent change. Hair does not, because the follicle reports on its own clock — a cycle takes years and a change in the endocrine environment takes months to express as visible shaft calibre. Ninety days is the minimum honest assessment window for anything in this field, and for a metabolic intervention aimed at hair, six to twelve months is the realistic horizon. Photograph your part monthly under fixed conditions, because that is a change too slow for memory.

The Bottom Line

Insulin resistance affects hair through a specific, well-characterised route: chronically elevated insulin suppresses hepatic production of sex hormone-binding globulin, less SHBG means a larger free fraction of testosterone, and more free testosterone means more substrate for 5-alpha-reductase at follicles that are genetically sensitive to DHT. Total testosterone can look entirely normal throughout.

The observational literature linking pattern hair loss to metabolic markers is suggestive rather than conclusive, and should be read as such. The mechanism, however, is established independently of it.

Ask for fasting insulin — it is the test that detects the compensated phase, and it is usually the one nobody ordered. Add fasting glucose, HbA1c, a lipid panel, waist circumference and blood pressure. If there are irregular cycles, acne or hirsutism, read the PCOS article and pursue that assessment.

Then treat the metabolic problem as a metabolic problem: resistance training, glycaemic load rather than calorie counting alone, sleep treated as physiology, and gradual rather than punishing weight change. Your follicles are downstream of all of it — and unlike your genes, this part of the chain is genuinely modifiable.

Dr. Susan Lin's Clinical Perspective

"The single most useful test I can persuade a patient to ask for is fasting insulin, and it is almost never on the panel she arrives with. Normal glucose tells you the system is still compensating; it tells you nothing about how hard it is working to compensate, and the years spent in that compensated state are exactly the years the follicle is exposed to a raised free androgen fraction. What I want women to understand is where the leverage sits. You cannot change the androgen receptor density in your scalp. You can change how much sex hormone-binding globulin your liver is making, and you change it with muscle, sleep and the shape of your meals rather than with a prescription. That is an unusually good position to be in, and it is worth knowing you are in it."

— Dr. Susan F. Lin, M.D., Physician Formulator, MD HAIR

Mechanism Spotlight: How the Liver Sets Your Follicles' Androgen Exposure

The organ that most influences how much androgen reaches your scalp is not the ovary or the adrenal. It is the liver.

Sex hormone-binding globulin is a glycoprotein synthesised by hepatocytes and secreted into the circulation, where it binds dihydrotestosterone and testosterone with high affinity and oestradiol with somewhat lower affinity. The great majority of circulating testosterone is bound — to SHBG tightly and to albumin loosely — leaving only a small free fraction able to diffuse into target tissues. Because the free fraction is small, a modest change in SHBG concentration produces a proportionally much larger change in free hormone, with total testosterone unchanged.

Insulin regulates this directly at the hepatocyte. Work in the HepG2 human hepatoma line demonstrated that insulin inhibits SHBG production by these cells (Plymate et al., 1988), and clinical work showed the converse in vivo: lowering circulating insulin in women with polycystic ovary syndrome raised serum SHBG, indicating that hyperinsulinaemia was actively suppressing it (Nestler et al., 1991). Reviews of the field describe the inverse association between insulin resistance and SHBG as one of its more reproducible relationships (Wallace et al., 2013).

At the follicle, the consequence is a matter of substrate supply. 5-alpha-reductase in the dermal papilla and outer root sheath converts available testosterone to DHT; DHT then binds the androgen receptor and, in follicles carrying the regional genetic sensitivity, shortens successive anagen phases and drives miniaturization (Sawaya & Price, 1997).

The clinically important feature of this pathway is that it is bidirectional and modifiable. SHBG is not a fixed trait. Interventions that lower circulating insulin — improved insulin sensitivity through resistance exercise, reduced glycaemic load, restored sleep, visceral fat reduction — raise SHBG, and a higher SHBG reduces the free androgen fraction delivered to the scalp. That is a longer causal chain than any topical, and it is the one that runs through choices you make daily.

MD HAIR Product Recommendation

MD Nutri Hair™ — /products/nutri-hair-supplement

I want to be precise about what a supplement can and cannot contribute to what this article describes, because the honest answer is bounded. MD Nutri Hair™ is not a treatment for insulin resistance and will not change your SHBG. The metabolic work in this article is done by resistance training, glycaemic load, sleep and, where relevant, gradual weight change, and there is no capsule that substitutes for any of it.

What it is for is the other end of the chain — the environment around the follicle while you do that work. Its lilac component is standardized for verbascoside, a plant phenol which in controlled laboratory studies on human dermal papilla cells reduced the release of pro-inflammatory signals including IL-1α, IL-6, IL-1β and TNF-α, induced cell proliferation, and prevented testosterone-induced cell death. Those are cell studies in a dish, not human trials; the authors state that clinical study is still needed, and the verbascoside studied came from Acanthus rather than lilac — the same molecule from a different botanical source, and not a study of our own material (Wisuitiprot et al., 2022). Given that this article is about a mechanism whose end point is androgen exposure and inflammation at the dermal papilla, that laboratory finding is the reason the product belongs on this page at all — and its limits are the reason I have stated them first.

The formula: a once-daily capsule built on a 300 mg proprietary blend, with vitamin B3 as niacinamide, vitamin E as alpha tocopheryl acetate, and D-biotin at 0.05 mg — a sensible cofactor dose rather than a megadose, which matters specifically here because high-dose biotin can distort exactly the immunoassays this article asks you to go and have done. Other ingredients: flaxseed powder, lignan powder, lilac. In the MD Nutri Hair™ 30-day in-office consumer use study (30 subjects, self-reported), 95% saw improved hair appearance, 90% reported better manageability, and 75% reported increased fullness. Individual results vary. As a dietary supplement it is not intended to diagnose, treat, cure, or prevent any disease, and it is not FDA approved — no dietary supplement is. Label warning: keep out of the reach of children. Do not take if you are pregnant or breast feeding. For adults only; one capsule daily. Physician-formulated by Dr. Susan F. Lin, M.D. under the MD® mark (U.S. Reg. No. 4,471,494) and manufactured in FDA-registered, GMP-compliant facilities.

A note on the assessment window: ninety days is the minimum honest period in which to judge anything in this category, mine included — and for a metabolic intervention aimed at hair, plan on six to twelve months.

A note on authenticity: genuine MD HAIR™ and MD Nutri Hair™ products are sold only through mdhair.com, md-factor.com, and the official La Cañada Ventures, Inc. stores on Amazon and Walmart. We cannot verify the storage, handling, labelling or lot integrity of units bought anywhere else.

Not sure where your thinning fits? Take the MD HAIR Quiz — a starting point for reasoning, not a diagnosis.

Learn more about hormonal hair loss at mdhair.com/pages/hormonal-hair-loss

References

Alberti KGMM, Eckel RH, Grundy SM, et al. (2009). Harmonizing the metabolic syndrome: a joint interim statement. Circulation, 120(16), 1640–1645. PMID 19805654
Plymate SR, Matej LA, Jones RE, Friedl KE. (1988). Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. Journal of Clinical Endocrinology and Metabolism, 67(3), 460–464. PMID 2842359
Nestler JE, Powers LP, Matt DW, et al. (1991). A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 72(1), 83–89. PMID 1898744
Wallace IR, McKinley MC, Bell PM, Hunter SJ. (2013). Sex hormone binding globulin and insulin resistance. Clinical Endocrinology, 78(3), 321–329. PMID 23121642
Matilainen V, Koskela P, Keinänen-Kiukaanniemi S. (2000). Early androgenetic alopecia as a marker of insulin resistance. The Lancet, 356(9236), 1165–1166. PMID 11030300
González-González JG, Mancillas-Adame LG, Fernández-Reyes M, et al. (2009). Androgenic alopecia and insulin resistance in young men. Clinical Endocrinology, 71(4), 494–499. PMID 19094069
Arias-Santiago S, Gutiérrez-Salmerón MT, Castellote-Caballero L, Buendía-Eisman A, Naranjo-Sintes R. (2010). Androgenetic alopecia and cardiovascular risk factors in men and women. Journal of the American Academy of Dermatology, 63(3), 420–429. PMID 20619491
Sawaya ME, Price VH. (1997). Different levels of 5α-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. Journal of Investigative Dermatology, 109(3), 296–300. PMID 9284093
Spiegel K, Leproult R, Van Cauter E. (1999). Impact of sleep debt on metabolic and endocrine function. The Lancet, 354(9188), 1435–1439. PMID 10543671
Buxton OM, Pavlova M, Reid EW, Wang W, Simonson DC, Adler GK. (2010). Sleep restriction for 1 week reduces insulin sensitivity in healthy men. Diabetes, 59(9), 2126–2133. PMID 20585000
Trost LB, Bergfeld WF, Calogeras E. (2006). The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. Journal of the American Academy of Dermatology, 54(5), 824–844. PMID 16635664
Wisuitiprot V, Ingkaninan K, Chakkavittumrong P, Wisuitiprot W, Neungchamnong N, Chantakul R, Waranuch N. (2022). Effects of Acanthus ebracteatus Vahl. extract and verbascoside on human dermal papilla and murine macrophage. Scientific Reports, 12(1), 1491. PMID 35087085

Dr. Susan F. Lin, M.D. is the physician formulator behind MD HAIR and MD Nutri Hair™, product lines of La Cañada Ventures, Inc. — physician-formulated since 2008 under the MD® mark (U.S. Reg. No. 4,471,494). She trained at Boston University School of Medicine and is board-certified in Obstetrics & Gynecology and in Anti-Aging Medicine (A4M).

MD® products are cosmetics and dietary supplements manufactured in FDA-registered, GMP-compliant facilities. "FDA-registered" describes the facility, not the product: MD® products are not FDA approved, and no cosmetic or dietary supplement is. Individual results vary. MD Nutri Hair™ is a dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Because there are no clinical data in pregnant or breastfeeding women, we do not advocate using MD HAIR products during pregnancy or lactation.

This article is for educational purposes and does not constitute medical advice. Insulin resistance, metabolic syndrome and polycystic ovary syndrome are medical diagnoses requiring evaluation by a physician; nothing here is a substitute for that evaluation, and no dietary or exercise change should replace treatment your doctor has prescribed.

Explore more in our Hormonal & Life Stage Hair Loss series at mdhair.com/pages/hormonal-hair-loss